ScholarIQanswers from OpenAlex

Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression

PaperCitations, authors & open-access status

Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression have?

ScholarIQcitation count

Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression has 45 citations in the OpenAlex counts ScholarIQ stores.

When was Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression published?

ScholarIQyear

Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression has 2004 year in the ScholarIQ index.

What is the open-access status of Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression?

ScholarIQoa status

Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression has bronze oa status in the ScholarIQ index.

What is the DOI of Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression?

ScholarIQdoi

The DOI for Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression is on the source record.

What is the PMID of Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression?

ScholarIQpmid

The PMID for Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression is on the source record.

What is the OpenAlex record for Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression?

ScholarIQopenalex

The OpenAlex for Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial